The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common immune conditions.
An article from
Startup launches
The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common immune conditions.
Published June 22, 2026
Getty Images
Bionyra's $165M launch: A Sanofi alum, I&I candidates from China, one big catch-up
La biotech française Bionyra lève 143 millions d’euros pour s’attaquer aux maladies inflammatoires chroniques
Israeli-founded AI biotech Immunai launches drug-discovery collaboration | The Jerusalem Post
Biogen makes up to $1B deal for secretive anti-inflammatory biotech
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline - Biogen (NASDAQ:BIIB)
Autoimmune disease company Oblenio Bio clinches $62M led by Pfizer Ventures
TrueLab Biopharmaceutical Announces License Agreement with Bionyra Pharma for Two Next-Generation Monoclonal and Bispecific Antibodies for Immune-Mediated Inflammatory Diseases Valued up to $985 Million
Le fonds wavrien Vives participe à une Série A de 143 millions dans la biotech Bionyra Pharma
Nortiva purrs into action with long-acting Lynx platform salvaged from Langer startup
Immunai signs $15M AI drug discovery deal with Boehringer Ingelheim
Former Sanofi I&I exec Frédéric Marrache launches Bionyra with $165M to chase TL1A targets in IBD and eczema.
Avec cette enveloppe, la biotech veut amorcer la mise au point d’une nouvelle génération de biothérapies destinées à soigner les…
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.
The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of…
The collaboration will use Immunai’s single-cell AI platform to identify T-cell targets in cancer and autoimmune diseases.
Biogen pays up to $1B for secretive San Diego biotech RayThera, gaining three undisclosed anti-inflammatory candidates to expand…
